Physician profile
Robert Wulwick
NPI 1972577435
$2,475.35
in general payments reported to CMS, 2019-2025
29 companies · $421 in 2025
The $421 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $120 · 2021: $239 · 2022: $347 · 2023: $497 · 2024: $270 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.95 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.58 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $349.08 | 2022-2024 | |
| Evofem Biosciences, INC. | $253.68 | 2021-2025 | Phexxi, Solosec, Phexx |
| Roche Diagnostics Corporation | $229.27 | 2019-2020 | |
| Astellas Pharma US INC | $227.16 | 2023-2025 | Veozah |
| Biogen, INC. | $166.66 | 2025 | Zurzuvae |
| Pfizer INC. | $104.00 | 2019-2023 | |
| Scynexis, INC. | $96.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.32 | 2023-2025 | |
| Coopersurgical, INC. | $65.90 | 2019-2022 | |
| Therapeuticsmd, INC. | $62.01 | 2019-2020 | |
| Avion Pharmaceuticals | $52.50 | 2022 | |
| Amag Pharmaceuticals, INC. | $51.61 | 2019-2020 | |
| Exeltis, USA INC. | $45.82 | 2024 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $36.27 | 2024 | Vpriv |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $35.63 | 2019 | |
| Organon LLC | $27.74 | 2024 | |
| Vertical Pharmaceuticals, LLC | $27.54 | 2019 | |
| Virtus Pharmaceuticals LLC | $24.50 | 2022 | |
| Allergan, INC. | $23.28 | 2019 | |
| Agile Therapeutics, INC. | $21.02 | 2023 | Twirla |
| Lupin INC. | $16.54 | 2019 | |
| Genzyme Corporation | $16.41 | 2023 | |
| Mission Pharmacal Company | $15.71 | 2019 | |
| Sumitomo Pharma America, INC. | $15.50 | 2023 | Myfembree |
| Exact Sciences Corporation | $15.20 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $14.49 | 2019 | |
| Millicent US INC | $13.48 | 2025 | Femlyv |
| Myovant Sciences INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wulwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.